A compendium of myeloma-associated chromosomal copy number abnormalities and their prognostic value

  • Brian A. Walker
    Section of Haemato-Oncology, The Institute of Cancer Research, London, United Kingdom;
  • Paola E. Leone
    Section of Haemato-Oncology, The Institute of Cancer Research, London, United Kingdom;
  • Laura Chiecchio
    Leukaemia Research Fund UK Myeloma Forum Cytogenetics Group, Wessex Regional Cytogenetic Laboratory, Salisbury, United Kingdom; and
  • Nicholas J. Dickens
    Section of Haemato-Oncology, The Institute of Cancer Research, London, United Kingdom;
  • Matthew W. Jenner
    Section of Haemato-Oncology, The Institute of Cancer Research, London, United Kingdom;
  • Kevin D. Boyd
    Section of Haemato-Oncology, The Institute of Cancer Research, London, United Kingdom;
  • David C. Johnson
    Section of Haemato-Oncology, The Institute of Cancer Research, London, United Kingdom;
  • David Gonzalez
    Section of Haemato-Oncology, The Institute of Cancer Research, London, United Kingdom;
  • Gian Paolo Dagrada
    Leukaemia Research Fund UK Myeloma Forum Cytogenetics Group, Wessex Regional Cytogenetic Laboratory, Salisbury, United Kingdom; and
  • Rebecca K. M. Protheroe
    Leukaemia Research Fund UK Myeloma Forum Cytogenetics Group, Wessex Regional Cytogenetic Laboratory, Salisbury, United Kingdom; and
  • Zoe J. Konn
    Leukaemia Research Fund UK Myeloma Forum Cytogenetics Group, Wessex Regional Cytogenetic Laboratory, Salisbury, United Kingdom; and
  • David M. Stockley
    Leukaemia Research Fund UK Myeloma Forum Cytogenetics Group, Wessex Regional Cytogenetic Laboratory, Salisbury, United Kingdom; and
  • Walter M. Gregory
    Clinical Trials Research Unit, University of Leeds, Leeds, United Kingdom
  • Faith E. Davies
    Section of Haemato-Oncology, The Institute of Cancer Research, London, United Kingdom;
  • Fiona M. Ross
    Leukaemia Research Fund UK Myeloma Forum Cytogenetics Group, Wessex Regional Cytogenetic Laboratory, Salisbury, United Kingdom; and
  • Gareth J. Morgan
    Section of Haemato-Oncology, The Institute of Cancer Research, London, United Kingdom;

説明

<jats:title>Abstract</jats:title> <jats:p>To obtain a comprehensive genomic profile of presenting multiple myeloma cases we performed high-resolution single nucleotide polymorphism mapping array analysis in 114 samples alongside 258 samples analyzed by U133 Plus 2.0 expression array (Affymetrix). We examined DNA copy number alterations and loss of heterozygosity (LOH) to define the spectrum of minimally deleted regions in which relevant genes of interest can be found. The most frequent deletions are located at 1p (30%), 6q (33%), 8p (25%), 12p (15%), 13q (59%), 14q (39%), 16q (35%), 17p (7%), 20 (12%), and 22 (18%). In addition, copy number-neutral LOH, or uniparental disomy, was also prevalent on 1q (8%), 16q (9%), and X (20%), and was associated with regions of gain and loss. Based on fluorescence in situ hybridization and expression quartile analysis, genes of prognostic importance were found to be located at 1p (FAF1, CDKN2C), 1q (ANP32E), and 17p (TP53). In addition, we identified common homozygously deleted genes that have functions relevant to myeloma biology. Taken together, these analyses indicate that the crucial pathways in myeloma pathogenesis include the nuclear factor-κB pathway, apoptosis, cell-cycle regulation, Wnt signaling, and histone modifications. This study was registered at http://isrctn.org as ISRCTN68454111.</jats:p>

収録刊行物

  • Blood

    Blood 116 (15), e56-e65, 2010-10-14

    American Society of Hematology

被引用文献 (7)*注記

もっと見る

詳細情報 詳細情報について

問題の指摘

ページトップへ